Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06947980
PHASE2
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Keymed Biosciences Co.Ltd
View on ClinicalTrials.gov
Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-06-19
Completion Date
2026-11-07
Last Updated
2025-08-17
Healthy Volunteers
No
Conditions
Interventions
DRUG
Placebo Comparator
Placebo subcutaneous injection
BIOLOGICAL
CM512
CM512 subcutaneous injection
Locations (1)
Peking University People's hospital
Beijing, China